Sofiva Genomics Co Ltd

Sofiva Genomics maintains a strong liquidity position, with a current ratio of 3.33 and cash and equivalents of TWD 90.6 million, representing 12.5% of total assets. The company’s debt-to-equity ratio is 0.06, indicating minimal leverage and a conservative capital structure. Free cash flow of TWD 18.1 million and operating cash flow of TWD 15.4 million suggest positive cash generation despite a net loss of TWD 9.36 million. Profitability metrics show a return on equity of -1.49% and return on assets of -1.29%, both below the industry median for Biotechnology & Medical Research firms, which typically report positive ROE and ROA in the 5-10% range. Gross profit of TWD 99.1 million represents 25.7% of revenue, but operating losses persist due to high R&D and SG&A expenses. The company’s revenue is concentrated in domestic Taiwan operations, with no disclosed international revenue segments. No material geographic diversification is evident in the financial snapshot, and no segment-specific revenue breakdown is provided in the latest filings. Revenue for the latest period was TWD 385.7 million, with no year-over-year growth data available. The outlook for the current fiscal year is neutral, with no significant revenue acceleration or contraction expected. No forward-looking guidance is provided in the latest filings, and historical growth trends are not disclosed. Risk factors include low liquidity risk and low dilution potential, with no immediate filing-based flags detected. The company has no near-term debt maturities and no dilutive instruments outstanding, as shares outstanding remain unchanged between basic and diluted counts. Recent events include the latest financial filing (HA-latest), which discloses the current operating loss and cash position. No material regulatory or litigation events are flagged in the risk assessment, and no recent earnings call transcripts or press releases are included in the input data.